Clinical Effectiveness of Erlova in EGFR-Mutated Non-Small Cell Lung Cancer: An Affordable Price with Clinical Benefit.

Sharareh Seifi,Babak Salimi,Zahra Esfahani-Monfared,Ramin Radmanesh, Saeed Yaghoubifard, Sara Talebianpour,Adnan Khosravi

Asian Pacific journal of cancer prevention : APJCP（2022）

引用 0|浏览7

暂无评分

摘要

Our findings showed Erlova had remarkable effectiveness. In mutation-positive patients with EGFR, Erlova can be used safely instead of other tyrosine-kinase inhibitors.

查看译文

关键词

Carcinoma,Erlotinib Hydrochloride,Non-Small-Cell Lung,safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要